{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:11:02Z","timestamp":1793045462431,"version":"4.5.0"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,4,15]]},"DOI":"10.2169\/internalmedicine.3867-24","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T22:08:41Z","timestamp":1744668521000},"page":"1133-1141","source":"Crossref","is-referenced-by-count":4,"title":["The Effect of MAFLD on Hepatocarcinogenesis in HBeAg-negative Patients with Undetectable HBV-DNA under NA Therapy: A Multicenter Study"],"prefix":"10.2169","volume":"64","author":[{"given":"Keisuke","family":"Amano","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"},{"name":"Consulting and Support Center for Liver Diseases Fukuoka, Kurume University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoya","family":"Sano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"},{"name":"Consulting and Support Center for Liver Diseases Fukuoka, Kurume University Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ide","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"},{"name":"Consulting and Support Center for Liver Diseases Fukuoka, Kurume University Hospital, Japan"},{"name":"Kurume University Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nakano","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Tsutsumi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruko","family":"Arinaga-Hino","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Public Yame General Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Miyajima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kumamoto Central Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Torimura","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Omuta City Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Chan SL, Wong VW, Qin S, Chan HL. Infection and cancer: the case of hepatitis B. J Clin Oncol 34: 83-90, 2016.","DOI":"10.1200\/JCO.2015.61.5724"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Lindsay JA. Transmission of antimicrobial resistance in resource-poor healthcare. Trends Microbiol 23: 69-70, 2015.","DOI":"10.1016\/j.tim.2015.01.001"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Papatheodoridis GV, Dalekos GN, Yurdaydin C, et al. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. J Hepatol 62: 363-370, 2015.","DOI":"10.1016\/j.jhep.2014.08.045"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 64: 800-806, 2016.","DOI":"10.1016\/j.jhep.2015.11.035"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Voulgaris T, Papatheodoridi M, Lampertico P, Papatheodoridis GV. Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int 40: 484-495, 2020.","DOI":"10.1111\/liv.14334"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 384: 2053-2063, 2014.","DOI":"10.1016\/S0140-6736(14)60220-8"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Choi HSJ, Brouwer WP, Zanjir WMR, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology 71: 539-548, 2020.","DOI":"10.1002\/hep.30857"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Campbell C, Wang T, McNaughton AL, Barnes E, Matthews PC. Risk factors for the development of hepatocellular carcinoma (HCC) in chronic hepatitis B virus (HBV) infection: a systematic review and meta-analysis. J Viral Hepat 28: 493-507, 2021.","DOI":"10.1111\/jvh.13452"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Kim K, Choi S, Park SM. Association of high body mass index and hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a Korean population-based cohort study. JAMA Oncol 4: 737-739, 2018.","DOI":"10.1001\/jamaoncol.2018.0035"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kim NH, Cho YK, Kim BI, Kim HJ. Effect of metabolic syndrome on the clinical outcomes of chronic hepatitis B patients with nucleos(t)ide analogues treatment. Dig Dis Sci 63: 2792-2799, 2018.","DOI":"10.1007\/s10620-018-5165-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 73: 202-209, 2020.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Yamamura S, Eslam M, Kawaguchi T, et al. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 40: 3018-3030, 2020.","DOI":"10.1111\/liv.14675"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Lv H, Jiang Y, Zhu G, et al. Liver fibrosis is closely related to metabolic factors in metabolic associated fatty liver disease with hepatitis B virus infection. Sci Rep 13: 1388, 2023.","DOI":"10.1038\/s41598-023-28351-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep 3: 100350, 2021.","DOI":"10.1016\/j.jhepr.2021.100350"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection. Hepatol Res 44 Suppl S1: 1-58, 2014.","DOI":"10.1111\/hepr.12269"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update. Liver Cancer 10: 181-223, 2021.","DOI":"10.1159\/000514174"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 46: 32-36, 2007.","DOI":"10.1002\/hep.21669"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Araki E, Goto A, Kondo T, et al. Japanese clinical practice guideline for diabetes 2019. Diabetol Int 11: 165-223, 2020.","DOI":"10.1007\/s13340-020-00439-5"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis 42: 503-508, 2010.","DOI":"10.1016\/j.dld.2009.08.002"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Suh B, Park S, Shin DW, et al. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology 61: 1261-1268, 2015.","DOI":"10.1002\/hep.27654"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Tanaka J. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: an analysis using time-dependent receiver operating characteristic. J Gastroenterol Hepatol 32: 451-458, 2017.","DOI":"10.1111\/jgh.13473"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Chen CT, Chen JY, Wang JH, et al. Diabetes mellitus, metabolic syndrome and obesity are not significant risk factors for hepatocellular carcinoma in an HBV- and HCV-endemic area of Southern Taiwan. Kaohsiung J Med Sci 29: 451-459, 2013.","DOI":"10.1016\/j.kjms.2012.12.006"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Allen AM, Hicks SB, Mara KC, Larson JJ, Therneau TM. The risk of incident extrahepatic cancers is higher in non-alcoholic fatty liver disease than obesity - a longitudinal cohort study. J Hepatol 71: 1229-1236, 2019.","DOI":"10.1016\/j.jhep.2019.08.018"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Tan Y, Wei S, Zhang W, Yang J, Yang J, Yan L. Type 2 diabetes mellitus increases the risk of hepatocellular carcinoma in subjects with chronic hepatitis B virus infection: a meta-analysis and systematic review. Cancer Manag Res 11: 705-713, 2019.","DOI":"10.2147\/CMAR.S188238"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Fan R, Niu J, Ma H, et al. Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy. Aliment Pharmacol Ther 54: 329-338, 2021.","DOI":"10.1111\/apt.16469"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Yu MW, Lin CL, Liu CJ, Yang SH, Tseng YL, Wu CF. Influence of metabolic risk factors on risk of hepatocellular carcinoma and liver-related death in men with chronic hepatitis B: a large cohort study. Gastroenterology 153: 1006-1017 e1005, 2017.","DOI":"10.1053\/j.gastro.2017.07.001"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kim JH, Kim YD, Lee M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy. J Hepatol 69: 1066-1073, 2018.","DOI":"10.1016\/j.jhep.2018.07.018"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hsu YC, Yip TC, Ho HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol 69: 278-285, 2018.","DOI":"10.1016\/j.jhep.2018.02.032"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/8\/64_3867-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,19]],"date-time":"2025-04-19T03:29:38Z","timestamp":1745033378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/8\/64_3867-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3867-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"article-number":"3867-24"}}